Your session is about to expire
← Back to Search
Nelfinavir + Chemoradiation for Vulvar Cancer
Study Summary
This trial is testing nelfinavir, an antiviral drug, in combination with cisplatin and external beam radiation therapy to treat patients with vulvar cancer that has spread to nearby tissue or lymph nodes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am pregnant and do not plan to terminate the pregnancy before starting treatment.I have not had any cancer other than non-melanoma skin cancer in the past 5 years.My diabetes is not well-managed even with medication.I have a unique kidney shape or a kidney transplant affecting radiation treatment.My cancer is in its early stage and hasn't spread to lymph nodes.My cancer has spread to areas outside the initial radiation treatment zone.I have had radiation, chemotherapy, or any treatment for my cancer in the pelvic or abdominal area.I cannot take pills due to my GI condition, which affects how my body absorbs food.My kidney function is low, with an eGFR below 30.I have phenylketonuria.I am not taking medications like amiodarone, St John's wort, or lovastatin.My vulvar cancer is confirmed, not surgically removable, and at a certain stage.I do not have a severe infection or septicemia.I can take care of myself but may not be able to do heavy physical work.I have a tube or stent for my blocked ureter.I agreed to join the trial within 12 weeks of my diagnosis or have been recently reassessed.
- Group 1: Treatment (nelfinavir, cisplatin, EBRT)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the typical medical applications of Nelfinavir?
"Nelfinavir is a popular drug used to treat human immunodeficiency virus type 1 (hiv-1) infection. It also has been noted as effective in treating advanced ovarian cancer that resists standard treatments, and neoplasm metastasis."
Can you enlighten me as to any antecedent studies involving Nelfinavir?
"At the present moment, 749 clinical trials are underway to investigate Nelfinavir. Of those studies, 289 have progressed to Phase 3 testing. Although many of these experiments take place in Shanghai, there are also 44135 other sites conducting research on this drug."
What risks are posed by the utilization of Nelfinavir?
"Our specialists at Power gave Nelfinavir a grade of 1 due to being in Phase 1; minimal evidence exists regarding its safety and effectiveness."
Are they currently enrolling participants for this scientific experiment?
"Affirmative. The clinicaltrial.gov registry discloses that this research is currently recruiting subjects, with the inaugural post date of August 7th 2020 and a recent update on September 18th 2020. A total of eighteen volunteers are necessary for participation at only one site."
How many individuals have been approved to participate in this clinical trial?
"Affirmative. According to clinicaltrials.gov, the medical study is currently recruiting participants which was first listed on August 7th 2020 and last modified on September 18th 2020. The research requires 18 individuals from 1 centre."
Share this study with friends
Copy Link
Messenger